PRME

Prime Medicine, Inc.

Healthcare
Biotechnology
$565M market cap

Forecast run · Sep 15, 2026Upside rank 401 of 3,136

Model Signal

ForecastQ Daily Probabilities

58.4%

38.5%

34.3%

Analyst Consensus

Recommendation2.30/5 Buy

Last price$3.13

Price target$7.50

Implied move+139.6%

Analysts10

ForecastQ Portfolios

PRME is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.